Rubius Therapeutics Inc.

Plus: Amy Parison to succeed Lucera at Editas, and a new CEO at Akari 

Plus: Context hires Ullmann, Andreas, and updates from Galectin, Exagen, Candid, Amgen and Hummingbird

Plus: Airna, ReviR, LTZ and Synthetica draw Series A cash, while Outpace, Confo and Healx refill their coffers

Newly independent cancer biotech looks to twin 2025 readouts of IL-2 program that leads pipeline of engineered cytokine therapeutics

Plus: CureVac’s Splawski lands at Yarrow and updates from Genelux, Cour and more

Plus: Glanzmann takes the helm at Grifols and updates from Frontier, Inceptor, Zevra and AceLink

At year-end, twice as many of the companies had lost value since their IPOs than gained value 

Plus: new CFO at BioArctic and updates from Sutro, Korro, BioAtla, Claris, Akoya and more

Plus: Graphite terminates sickle cell program, FDA reviewing Pfizer’s bispecific, and updates from Zai Lab, Sherlock, Abivax and more

Plus: Carmona named CFO at ADC, and updates from NewAmsterdam, CRISPR, Ikena, CN bio and more